Biogen Inc (NASDAQ: BIIB) has a price-to-earnings ratio of 13.15x that is above its average ratio. Additionally, the 36-month beta value for BIIB is 0.13. There are mixed opinions on the stock, with 13 analysts rating it as a “buy,” 5 rating it as “overweight,” 19 rating it as “hold,” and 0 rating it as “sell.”
The public float for BIIB is 146.25M and currently, short sellers hold a 2.32% ratio of that float. The average trading volume of BIIB on July 03, 2025 was 1.64M shares.
BIIB) stock’s latest price update
Biogen Inc (NASDAQ: BIIB)’s stock price has gone rise by 2.40% in comparison to its previous close of $130.07, however, the company has experienced a 4.62% increase in its stock price over the last five trading days. zacks.com reported 2025-07-01 that BIIB begins phase III dosing of felzartamab primary membranous nephropathy study, targeting a tough-to-treat condition with no approved therapies.
BIIB’s Market Performance
Biogen Inc (BIIB) has seen a 4.62% rise in stock performance for the week, with a 1.56% gain in the past month and a 0.88% surge in the past quarter. The volatility ratio for the week is 3.60%, and the volatility levels for the past 30 days are at 2.65% for BIIB. The simple moving average for the last 20 days is 2.75% for BIIB’s stock, with a simple moving average of -10.35% for the last 200 days.
Analysts’ Opinion of BIIB
Many brokerage firms have already submitted their reports for BIIB stocks, with HSBC Securities repeating the rating for BIIB by listing it as a “Hold.” The predicted price for BIIB in the upcoming period, according to HSBC Securities is $118 based on the research report published on April 28, 2025 of the current year 2025.
Bernstein gave a rating of “Mkt Perform” to BIIB, setting the target price at $160 in the report published on February 11th of the current year.
BIIB Trading at 5.66% from the 50-Day Moving Average
After a stumble in the market that brought BIIB to its low price for the period of the last 52 weeks, the company was unable to rebound, for now settling with -44.04% of loss for the given period.
Insider Trading
Reports are indicating that there were more than several insider trading activities at BIIB starting from Singhal Priya, who sale 3,806 shares at the price of $126.25 back on May 19 ’25. After this action, Singhal Priya now owns 5,427 shares of Biogen Inc, valued at $480,508 using the latest closing price.
Stock Fundamentals for BIIB
Current profitability levels for the company are sitting at:
- 0.23 for the present operating margin
- 0.76 for the gross margin
The net margin for Biogen Inc stands at 0.15. The total capital return value is set at 0.1. Equity return is now at value 9.19, with 5.42 for asset returns.
Based on Biogen Inc (BIIB), the company’s capital structure generated 0.28 points at debt to capital in total, while cash flow to debt ratio is standing at 0.39. The debt to equity ratio resting at 0.39. The interest coverage ratio of the stock is 9.43.
Currently, EBITDA for the company is 2.83 billion with net debt to EBITDA at 1.49. When we switch over and look at the enterprise to sales, we see a ratio of 2.4. The receivables turnover for the company is 4.92for trailing twelve months and the total asset turnover is 0.35. The liquidity ratio also appears to be rather interesting for investors as it stands at 1.44.
Conclusion
In conclusion, Biogen Inc (BIIB) has seen mixed performance in recent times. Analysts have a mixed opinion on the stock, with some rating it as a “buy” and others rating it as a “hold”. It’s important to note that the stock is currently trading at a significant distance from its 50-day moving average and its 52-week high.
